Drugs / ARO-CFB
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06209177 | Apr 2024 → Mar 2025 | IgA glomerulonephritis | Arrowhead Pharmaceuticals | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2024-12-11 | Arrowhead Pharmaceuticals | Results Arrowhead Pharmaceuticals Presents Interim Clinical Data on ARO-CFB for the Treatment of Complement Mediated Diseases arrowheadpharma.com ↗ |
| 2023-12-21 | Arrowhead Pharmaceuticals | Regulatory Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-CFB for Complement Mediated Kidney Disease arrowheadpharma.com ↗ |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-12-11 | Arrowhead Pharmaceuticals | Arrowhead Pharmaceuticals Presents Interim Clinical Data on ARO-CFB for the Treatment of Complement Mediated Diseases arrowheadpharma.com ↗ |
| 2024-04-24 | Arrowhead Pharmaceuticals | Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease arrowheadpharma.com ↗ |
| 2023-12-21 | Arrowhead Pharmaceuticals | Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-CFB for Complement Mediated Kidney Disease arrowheadpharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ARO-CFB | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06209177 ↗ |
| Route | Subcutaneous | “1 or 2 doses of ARO-CFB by subcutaneous (sc) injection” NCT06209177 ↗ |